C4 | Jotup

NUTRABOLT EARNS GREAT PLACE TO WORK CERTIFICATION™

Retrieved on:

tisdag, april 26, 2022

AUSTIN, Texas, April 26, 2022 /PRNewswire/ -- Nutrabolt is proud to be Certified™ again by Great Place to Work®. The prestigious award is based entirely on what current teammates say about their experience working at Nutrabolt. This year, 89% of teammates said it's a great place to work – which is 32 percent higher than the average U.S. company.

Key Points:

AUSTIN, Texas, April 26, 2022 /PRNewswire/ -- Nutrabolt is proud to be Certified again by Great Place to Work.
"Great Place to Work Certification isn't something that comes easily it takes ongoing dedication to the employee experience," said Sarah Lewis-Kulin, Vice President of Global Recognition at Great Place to Work.
I'm proud of this achievement and believe Nutrabolt is truly a Great Place to Work", says Brittany Cullison, Chief People Officer at Nutrabolt.
According to Great Place to Work research, job seekers are 4.5 times more likely to find a great boss at a Certified great workplace.

VET Tv Announces Release of the C4 Foundation's Documentary Supporting Active-Duty Navy SEALs and Their Families in Memory of Charlie Humphrey Keating IV

Retrieved on:

fredag, april 22, 2022

The documentary showcases the Foundation's first-of-its kind program supporting Navy SEALs and their families.

Key Points:

The documentary showcases the Foundation's first-of-its kind program supporting Navy SEALs and their families.
"Our organization is honored to release the C4 Foundation's documentary on our platform," said Waco Hoover, CEO of VET Tv.
Partnering with VET TV allows us to reach the audience that understands our mission best", said Charlie Keating III, Founder of C4.
The C4 Foundation was founded by the family of Charles Humphrey Keating IV (C4), a Navy SEAL who heroically gave his life defending our freedom.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of C4 Therapeutics, Inc. - CCCC

Retrieved on:

onsdag, april 20, 2022

News, LLP, NASDAQ, Toxicity, GLOBE, Company, Patient, Infrared spectroscopy correlation table, Ongo, Neutropenia, Pomerantz, C4, Therapy, Pharmaceutical industry

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC).

Key Points:

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether C4 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

C4 ENERGY® ANNOUNCES KEVIN HART AS THE FACE OF "GET THAT HART SMART ENERGY" CAMPAIGN IN EXTENSION OF "IGNITE YOUR FIRE™" PLATFORM

Retrieved on:

tisdag, april 19, 2022

Athlete, Citicoline, Functional beverage, TikTok, Nutrabolt Stadium, Albertsons, OTT, Twitter, Caffeine, Kevin Hart, Element, DTC, Fire, LOL, The Vitamin Shoppe, Target, QuikTrip, Walmart, Ignite, GNC, Marketing, Digital, Safeway, Multimedia, Partnership, Face, Attention, C4, Kroger, Television, Toy, Walgreens, Instagram, Publix, Facebook, Amazon, Cellucor

AUSTIN, Texas, April 19, 2022 /PRNewswire/ -- Today, C4 Energy®, one of the fastest-growing energy drink brands in the United States, announces "Get That Hart Smart Energy," a multifaceted brand campaign fueled by the world's most recognized multi-hyphenate as the face - comedian, actor, entrepreneur, and producer, Kevin Hart. Through this campaign, which includes an epic multimedia digital program, C4 Energy and Kevin Hart want you to Ignite Your Fire and maximize your human potential by enhancing your mental performance with C4 Smart Energy.

Key Points:

Through this campaign, which includes an epic multimedia digital program, C4 Energy and Kevin Hart want you to Ignite Your Fire and maximize your human potential by enhancing your mental performance with C4 Smart Energy.
Hart manages to juggle the many facets of his life by incorporating C4 Smart Energy into his everyday routine, leveraging the drink to fuel his energetic lifestyle.
You might think it's super human to move as quickly as I do, but it's really C4 Smart Energy powering me through, helping me stay sharp and laser focused," said Kevin Hart.
C4 Smart Energy, including its newest flavor, Watermelon Burst, is available in all 50 states, internationally, and online at C4Energy.com .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of C4 Therapeutics, Inc. - CCCC

Retrieved on:

fredag, april 15, 2022

News, LLP, NASDAQ, Toxicity, GLOBE, Company, Patient, Infrared spectroscopy correlation table, Ongo, Neutropenia, CCCC, Pomerantz, C4, Therapy, Pharmaceutical industry

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC).

Key Points:

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether C4 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate

Retrieved on:

torsdag, april 14, 2022

SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, researchers from BGI-Research, together with scientific research teams from China, Germany, Italy, Singapore, Spain, Sweden and the UK, today published the world's first non-human primate whole-body cell transcriptomic atlas in the scientific journal Nature.

Key Points:

The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions.
This study and other large scale primate research at the single-cell level are only possible through developments in advanced sequencing technology, an area where BGI is a leader.
BGI's proprietary technology enables extensive and multi-dimensional single-cell analysis with high sensitivity and accuracy at a low cost.
"Having a whole-body organ single-cell map of the adult macaque will significantly improve the ability to pinpoint how to develop potential treatments for human diseases with greater precision."

International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate

Retrieved on:

torsdag, april 14, 2022

SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, researchers from BGI-Research, together with scientific research teams from China, Germany, Italy, Singapore, Spain, Sweden and the UK, today published the world's first non-human primate whole-body cell transcriptomic atlas in the scientific journal Nature.

Key Points:

This study and other large scale primate research at the single-cell level are only possible through developments in advanced sequencing technology, an area where BGI is a leader.
BGI's proprietary technology enables extensive and multi-dimensional single-cell analysis with high sensitivity and accuracy at a low cost.
Single-cell mapping allowed the team to identify the cell types that may contribute to human disease or make individuals more susceptible to the disease.
Likewise, this process could help identify which cells regulate neuronal circuits in the brain, leading to potential treatments for neurological diseases.

TPC Group Announces Extension to Forbearance Agreement

Retrieved on:

måndag, april 11, 2022

Company, FTI Consulting, TPC Group, Plastic, Simpson Thacher & Bartlett, GLOBE, Houston Ship Channel, Gulf Coast of the United States, C4

The Ad Hoc Group and the Company have agreed to extend the forbearance agreement through and including May 23, 2022.

Key Points:

The Ad Hoc Group and the Company have agreed to extend the forbearance agreement through and including May 23, 2022.
This additional period will allow TPC Group to continue engaging in constructive discussions with the aim of strengthening the Companys capital structure and positioning the Company to be a stronger, more competitive business.
TPC Group is a recognized global leader in producing value-added products and raw materials such as C4 hydrocarbons.
Furthermore, TPC Group provides critical infrastructure and logistics services to petrochemical operators along the Gulf Coast.

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

Retrieved on:

fredag, april 8, 2022

Private Securities Litigation Reform Act, Risk, Therapy, B-cell lymphoma, Hematology, Plasma, Research, Solar cycle 1, Winship Cancer Institute, Association, American Association for Cancer Research, Drug resistance, IKZF1, GLOBE, Mass spectrometry, Annual report, Disease, Security (finance), Plasmacytoma, Population, Infrared spectroscopy correlation table, American Association, Mantle cell lymphoma, Solar cycle 2, International Myeloma Foundation, MM, Lymphoma, U.S. Securities and Exchange Commission, Peripheral T-cell lymphoma, Toxicity, Dexamethasone, Investor, Death, ID, Clinical trial, Activity, NHL, AACR, Multiple myeloma, Webcast, Therapeutic index, CCCC, Oncology, IKZF3, Patient, Infection, FACP, Emory University, PK, Half-life, Fever, Cohort study, Neutropenia, Safety, Lenalidomide, Vaccine, Pharmaceutical industry, RRMM, Cohort, C4

WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455, a novel degrader targeting IKZF1/3 for the treatment of multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on Tuesday, April 12, 2022, at 9 AM CT by Sagar Lonial, M.D., FACP.

Key Points:

We continue to enroll patients in the ongoing clinical trial with the goal of providing a new treatment option for myeloma and lymphoma patients.
The Phase 1/2 trial is designed to primarily investigate safety, tolerability, and anti-tumor activity.
Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five patients with MM.
Summary of Data from Cohort A:
Four patients received single agent CFT7455 at the starting dose of 50 g per day.

SharpLink Gaming Announces C4 Integration with NASCAR.com Delivers 225% Increase in Qualified Sports Betting Depositors for BetMGM

Retrieved on:

tisdag, mars 29, 2022

Currently, SharpLink is featuring a BetMGM bet slip module on NASCAR.coms home page that incorporates C4 bet recommendation algorithms in states where online sports betting has been legalized.

Key Points:

Currently, SharpLink is featuring a BetMGM bet slip module on NASCAR.coms home page that incorporates C4 bet recommendation algorithms in states where online sports betting has been legalized.
Once a NASCAR fan clicks on the bet slip, a BetMGM promotional offer is provided to the potential bettor.
SharpLink's intelligent C4 Sports Betting Conversion technology delivers and determines the best sportsbook betting offers and experience for each identified user.
SharpLink is run by industry veterans with several successful exits in the sports gaming and iGaming sectors.